[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100436724":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":21,"centralContacts":26,"locations":10,"responsibleParty":35,"collaborators":39,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":5,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":62,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":10,"overallStatus":67,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":10},{"fullName":5,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"CAV 0(Not significant)",null,"No detectable angiographic lesion",{"label":13,"type":10,"description":14,"interventionNames":10},"CAV 1 (Mild)","Angiographic left main (LM) \\\u003C50%, or primary vessel with maximum lesion of \\\u003C70%, or any branch stenosis \\\u003C70% (including diffuse narrowing) without allograft dysfunction",{"label":16,"type":10,"description":17,"interventionNames":10},"CAV 2 (Moderate)","Angiographic LM \\\u003C50%; a single primary vessel≥70%, or isolated branch stenosis ≥70% in branches",{"label":19,"type":10,"description":20,"interventionNames":10},"CAV 3 (Severe)","Angiographic LM≥50%, or two or more primary vessels ≥70% stenosis, or isolated branch stenosis≥70%in all 3 systems; or CAV1 or CAV2 with allograft dysfunction (defined as LVEF≤45% usually in the presence of regional wall motion abnormalities) or evidence of significant restrictive physiology",[22],{"name":23,"affiliation":24,"role":25},"Li Zhang, PhD","Department of Ultrasound, Union Hospital, Wuhan, China","PRINCIPAL_INVESTIGATOR",[27,31],{"name":23,"role":28,"phone":29,"phoneExt":10,"email":30},"CONTACT","18907131488","zli429@hust.edu.cn",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},"Shuangshuang Zhu, MD","15971428009","18846032209@163.com",{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Xie Mingxing","MD, PhD,FACC, FAHA, FASE",[40,42,44,46,48],{"name":41,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"name":43,"class":6},"Shanghai Zhongshan Hospital",{"name":45,"class":6},"Henan Provincial People's Hospital",{"name":47,"class":6},"Wuhan Asia Heart Hospital",{"name":49,"class":6},"Guangdong Provincial People's Hospital","100436724","multimodal-imaging-evaluation-and-prognostic-analysis-of-cardiac-allograft-vasculopathy-in-heart-transplantation-100436724",false,"NCT04966988","Multimodal Imaging Evaluation and Prognostic Analysis of Cardiac Allograft Vasculopathy in Heart Transplantation","Inclusion Criteria:\n\n• Heart transplantation after January 1st, 2015.\n\nExclusion Criteria:\n\n•Age \\\u003C 18 years at the time of transplantation; Died within 48 h; Heart-lung transplantation; Heart\u002Fkidney transplantation; Re-transplanted within 7 days after transplantation.","ALL","18 Years","80 Years",{"count":60,"type":61},1000,"ESTIMATED","10 Years","OBSERVATIONAL","The aim is to (1) establish a system of multimodal imaging technology; (2) jointly apply multimodal imaging technology to diagnose of cardiac allograft vasculopathy of heart transplantation; (3) construct a multimodal imaging technology prediction model of adverse events, screening the best non-invasive imaging prediction indicators.",[66],"Heart Transplant","NOT_YET_RECRUITING","2021-07-16",{"date":70,"type":71},"2021-07-19","ACTUAL",{"date":73,"type":61},"2021-08-01",{"date":75,"type":61},"2026-08-01",{"name":37,"class":6}]